Millipore Sigma Vibrant Logo
Attention: We have moved. Merck Millipore products are no longer available for purchase on MerckMillipore.com.Learn More

574625 Suramin, Sodium Salt - CAS 129-46-4 - Calbiochem

A reversible and competitive inhibitor of protein tyrosine phosphatases.

FDS (Fiches de données de sécurité), certificats d’analyse (CoA) et de qualité (CoQ), dossiers, brochures et autres documents disponibles.

Synonymes: Purinergic Receptor P2Y Antagonist I, PTP Inhibitor VI, P2Y Antagonist I

Primary Target: protein tyrosine phosphatases
574625
Purchase on Sigma-Aldrich

Aperçu

Replacement Information

Tableau de caractéristiques principal

CAS #Empirical Formula
129-46-4C₅₁H₃₄N₆O₂₃S₆ . 6Na

Products

RéférenceConditionnement Qté
574625-50MG Ampoule plast. 50 mg
Description
OverviewA reversible and competitive inhibitor of protein tyrosine phosphatases. An anti-neoplastic, anti-angiogenic agent that uncouples G-proteins from receptors presumably by blocking their interaction with intracellular receptor domains. Inhibits GDP-GTP exchange, the rate limiting step in the activation of Gα-subunits. A competitive inhibitor of reverse transcriptase. Reported to inhibit topoisomerases I and II. Inhibits Ca2+-ATPase in sarcoplasmic reticulum membranes. Also inhibits the cell-surface binding of various growth factors, including EGF, PDGF, and TGF-β. An inhibitor of phospholipase D (IC50 = 15 µM). Reported to interact with ATP-binding enzymes and P2-purinergic receptors. An effective inhibitor of angiogenesis in the calmodulin assay when given in combination with angiostatic steroids.
Catalogue Number574625
Brand Family Calbiochem®
SynonymsPurinergic Receptor P2Y Antagonist I, PTP Inhibitor VI, P2Y Antagonist I
References
ReferencesMeyers, M.O., et al. 2000. J. Surg. Res. 91, 130.
Hohenegger, M., et al. 1998. Proc. Natl. Acad. Sci. USA 95, 346.
Waldhoer, M., et al. 1998. Mol. Pharmacol. 53, 808.
Zhang, Y.L., et al. 1998. J. Biol. Chem. 273, 12281.
Hohenegger, M., et al. 1996. Mol. Pharmacol. 50, 1443.
Emmick, J.J., et al. 1994. J. Pharmacol. Exp. Ther. 269, 717.
Denhertog, A., et al. 1992. J. Physiol. 454, 591.
Nakajima, M., et al. 1991. J. Biol. Chem. 266, 9661.
Wilks, J.W., et al. 1991. Int. J. Radiat. Biol. 60, 73.
Huang, R.C., et al. 1990. Mol. Pharmacol. 37, 304.
Kopp, R. and Pfeiffer, A. 1990. Cancer Res. 50, 6490.
Product Information
CAS number129-46-4
ATP CompetitiveN
FormWhite to beige to peach crystalline solid
Hill FormulaC₅₁H₃₄N₆O₂₃S₆ . 6Na
Chemical formulaC₅₁H₃₄N₆O₂₃S₆ . 6Na
Hygroscopic Hygroscopic
ReversibleY
Structure formula ImageStructure formula Image
Quality LevelMQ100
Applications
Biological Information
Primary Targetprotein tyrosine phosphatases
Primary Target IC<sub>50</sub>15 µM against phospholipase D
Purity≥98% by HPLC
Physicochemical Information
Cell permeableN
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
RTECSQM7000000
Safety Information
Product Usage Statements
Storage and Shipping Information
Ship Code Ambient Temperature Only
Toxicity Standard Handling
Storage +2°C to +8°C
Hygroscopic Hygroscopic
Do not freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 1 month at -20°C.
Packaging Information
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
Référence GTIN
574625-50MG 04055977189636

Documentation

Suramin, Sodium Salt - CAS 129-46-4 - Calbiochem FDS

Titre

Fiche de données de sécurité des matériaux (FDS) 

Suramin, Sodium Salt - CAS 129-46-4 - Calbiochem Certificats d'analyse

TitreNuméro de lot
574625

Références bibliographiques

Aperçu de la référence bibliographique
Meyers, M.O., et al. 2000. J. Surg. Res. 91, 130.
Hohenegger, M., et al. 1998. Proc. Natl. Acad. Sci. USA 95, 346.
Waldhoer, M., et al. 1998. Mol. Pharmacol. 53, 808.
Zhang, Y.L., et al. 1998. J. Biol. Chem. 273, 12281.
Hohenegger, M., et al. 1996. Mol. Pharmacol. 50, 1443.
Emmick, J.J., et al. 1994. J. Pharmacol. Exp. Ther. 269, 717.
Denhertog, A., et al. 1992. J. Physiol. 454, 591.
Nakajima, M., et al. 1991. J. Biol. Chem. 266, 9661.
Wilks, J.W., et al. 1991. Int. J. Radiat. Biol. 60, 73.
Huang, R.C., et al. 1990. Mol. Pharmacol. 37, 304.
Kopp, R. and Pfeiffer, A. 1990. Cancer Res. 50, 6490.

Fiche technique

Titre
SIRTainty™ Class III HDAC Assay
Fiche technique

Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

Revision13-October-2020 JSW
SynonymsPurinergic Receptor P2Y Antagonist I, PTP Inhibitor VI, P2Y Antagonist I
DescriptionAn anti-neoplastic, anti-angiogenic agent that uncouples G-proteins from receptors presumably by blocking their interaction with intracellular receptor domains. A competitive inhibitor of reverse transcriptase. Reported to inhibit topoisomerase I and II. Inhibits Ca2+-ATPase in sarcoplasmic reticulum membranes. Also inhibits the cell-surface binding of various growth factors including EGF, PDGF, and TGF-β. An inhibitor of phospholipase D (IC50 = 15 µM). Reported to interact with ATP-binding enzymes and P2-purinergic receptors. An effective inhibitor of angiogenesis in calmodulin assays when given in combination with angiostatic steroids.
FormWhite to beige to peach crystalline solid
CAS number129-46-4
RTECSQM7000000
Chemical formulaC₅₁H₃₄N₆O₂₃S₆ . 6Na
Structure formulaStructure formula
Purity≥98% by HPLC
SolubilityH₂O (5 mg/ml)
Storage +2°C to +8°C
Hygroscopic
Do Not Freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 1 month at -20°C.
Toxicity Standard Handling
Merck USA index14, 9006
ReferencesMeyers, M.O., et al. 2000. J. Surg. Res. 91, 130.
Hohenegger, M., et al. 1998. Proc. Natl. Acad. Sci. USA 95, 346.
Waldhoer, M., et al. 1998. Mol. Pharmacol. 53, 808.
Zhang, Y.L., et al. 1998. J. Biol. Chem. 273, 12281.
Hohenegger, M., et al. 1996. Mol. Pharmacol. 50, 1443.
Emmick, J.J., et al. 1994. J. Pharmacol. Exp. Ther. 269, 717.
Denhertog, A., et al. 1992. J. Physiol. 454, 591.
Nakajima, M., et al. 1991. J. Biol. Chem. 266, 9661.
Wilks, J.W., et al. 1991. Int. J. Radiat. Biol. 60, 73.
Huang, R.C., et al. 1990. Mol. Pharmacol. 37, 304.
Kopp, R. and Pfeiffer, A. 1990. Cancer Res. 50, 6490.